Old Web
English
Sign In
Acemap
>
authorDetail
>
Peter Kelemen
Peter Kelemen
MorphoSys
Medicine
Phases of clinical research
Idelalisib
Venetoclax
Cancer research
6
Papers
10
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
2021
Leukemia & Lymphoma
Philipp B. Staber
Wojciech Jurczak
Richard Greil
Vladan Vucinic
Jan Moritz Middeke
Marco Montillo
Talha Munir
Peter Neumeister
Johannes Schetelig
Stephan Stilgenbauer
Frank Striebel
Maren Dirnberger-Hertweck
Johannes Weirather
Wolfram Brugger
Peter Kelemen
Clemens-Martin Wendtner
Jennifer A. Woyach
Show All
Source
Cite
Save
Citations (0)
Two-Cohort Phase II Study in R/R CLL (COSMOS): First Preliminary Safety and Efficacy Results of Anti-CD19 MOR208 Treatment in Combination with Venetoclax in Patients Who Discontinued Prior BTK Inhibitor Therapy
2018
Blood
Philipp B. Staber
Asher Chanan-Khan
Talha Munir
Dietger Niederweiser
Johannes Schetelig
Jan-Moritz Middeke
Maren Dirnberger-Hertweck
Peter Kelemen
Johannes Weirather
Sameer A. Parikh
Stephan Stilgenbauer
Clemens-Martin Wendtner
Jennifer A. Woyach
Show All
Source
Cite
Save
Citations (2)
A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE).
2016
Journal of Clinical Oncology
Clemens-Martin Wendtner
John C. Byrd
Barbara Eichhorst
Robin Foà
Michael Hallek
Peter Hillmen
Ulrich Jäger
Wojciech Jurczak
Peter Kelemen
Kamel Laribi
Talha Munir
Philipp B. Staber
Stephan Stilgenbauer
Jennifer A. Woyach
Show All
Source
Cite
Save
Citations (0)
Effect of octreotide LAR on quality of life of 93 Hungarian patients with neuroendocrine tumors.
2012
Journal of Clinical Oncology
Tibor Gyokeres
Sonia Pulgar
Neha Singh
Vanessa Q. Passos
Peter Kelemen
Show All
Source
Cite
Save
Citations (1)
1